Home/Pipeline/AIPCs / T1 Diabetes Autologous Transplant

AIPCs / T1 Diabetes Autologous Transplant

Type 1 Diabetes

Pre-clinicalActive

Key Facts

Indication

Type 1 Diabetes

Phase

Pre-clinical

Status

Active

Company

Imagine Pharma

About Imagine Pharma

Imagine Pharma is a private, pre-clinical stage biotech leveraging a novel polypeptide (IMG-1) to build three distinct therapeutic platforms: Oral Delivery of biologics, novel Therapeutics, and Regenerative Medicine. Its pipeline includes early-stage programs for oral EPO, skin grafts, diabetic wounds, and autologous islet transplants for Type 1 Diabetes. The company appears to be pre-revenue, focusing on R&D and seeking partnerships to advance its broad portfolio of platform-derived programs.

View full company profile

Therapeutic Areas

Anemia Diabetes Wound Healing Burns Endocrine Disorders

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
eRapa	Biodexa Pharmaceuticals	Preclinical	Research
ImmCelz™	Creative Medical Technology Holdings	Clinical Trial	Active
Adimune (ADi-001/002)	Aditxt	Preclinical / Early Clinical	Active
MSC‑Diabetes	Advancells	Phase 1	Active
BioChaperone® Lispro (THDB0206)	Adocia	Phase 3	Active
AdoShell® Islet Cell Therapy	Adocia	Preclinical	Platform Development
Pediatric Indications (<2 years)	Tandem Diabetes	Research	Exploratory
Icovamenib (BMF-219)	Biomea Fusion	Phase 2	Completed Follow-up, Data Pending
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research
Sotagliflozin	Lexicon Pharmaceuticals	Phase 3	Regulatory Path Uncertain
Stem Cell-Derived Beta Cells	BioTalentum	Pre-clinical	Active
NICHE	Continuity Biosciences	Pre-clinical	Active